This article is more than 5 years old. Information may no longer be current.
CyPass recall tops 2018 glaucoma news
Click Here to Manage Email Alerts
Alcon called for a voluntary withdraw of its CyPass micro-stent in August after data found significant endothelial cell loss 5 years after implantation. The news was the most-read glaucoma-related article on Healio.com/OSN in 2018.
Here are the top five glaucoma stories of the year:
Alcon calls for surgeons to stop implanting CyPass micro-stent
Citing “uncompromising commitment to patient safety,” Alcon has announced an immediate, voluntary withdrawal of all versions of the CyPass micro-stent from the global market and advises surgeons to immediately cease further implantation of the device. Read more.
Xelpros gains FDA approval for open-angle glaucoma, ocular hypertension
Xelpros (latanoprost ophthalmic solution 0.005%) is the first latanoprost product not formulated with the preservative benzalkonium chloride and was developed with SPARC’s Swollen Micelle Microemulsion technology. Read more.
Early follow-up after Xen implantation needed
Nearly 80% of patients who received a Xen gel stent with IOP-lowering topical medication after surgery experienced an IOP of less than 18 mm Hg, but early interventions were needed in 20% of patients. Read more.
FDA approves Hydrus microstent
The approval of the MIGS device was based on the results of the HORIZON trial, which included 556 mild to moderate glaucoma patients who underwent cataract surgery. Read more.
Imprimis dispensing glaucoma medications on FDA drug shortage list
Imprimis Pharmaceuticals is now dispensing preservative-free dorzolamide and a preservative-free dorzolamide/timolol formulation after dorzolamide was added to the FDA drug shortage list. Read more.